1,968
Views
17
CrossRef citations to date
0
Altmetric
Editorial

Shortcomings of pertussis vaccines: why we need a third generation vaccine

References

  • World Health Organisation. WHO vaccine-preventable diseases: monitoring system 2013 global summary. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules [Last accessed 20 May 2014]
  • Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996;45:1-35
  • Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003;21:2003-14
  • Sato Y, Sato H. Development of acellular pertussis vaccines. Biologicals 1999;27:61-9
  • Baxter P. Pertussis vaccine encephalopathy: ‘Oh! Let us never, never doubt’. Dev Med Child Neurol 2010;52:883-4
  • Cherry JD. Historical review of pertussis and the classical vaccine. J Infect Dis 1996;174 Suppl 3:S259-63
  • Kendrick PL, Eldering G, Dixon MK, Misner J. Mouse Protection Tests in the Study of Pertussis Vaccine: a Comparative Series Using the Intracerebral Route for Challenge. Am J Public Health Nations Health 1947;37:803-10
  • Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996;334:341-8
  • Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55
  • Bentsi-Enchill AD, Halperin SA, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997;15:301-6
  • Vaccinatie tegen kinkhoest. Den Haag: gezondheidsraad. Health Council of the Netherlands; 2004. Available from: www.gezondheidsraad.nl/sites/default/files/0404nadden.pdf [Last accessed 20 May 2014]
  • Corbel MJ, Xing DKL. Toxicity and potency evaluation of pertussis vaccines. Expert Rev Vaccines 2004;3:89-101
  • Guiso N, Capiau C, Carletti G, et al. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 1999;17:2366-76
  • Denoël P, Godfroid F, Guiso N, et al. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine 2005;23:5333-41
  • Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012;367:1012-19
  • Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012;308:454-6
  • Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013;368:581-2
  • Liko J, Robison SG, Cieslak PR. Pertussis vaccine performance in an epidemic year – Oregon, 2012. Clin Infect Dis 2014;59(2):261-3
  • Ward JI, Cherry JD, Chang S-J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005;353:1555-63
  • Ibsen PH. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 1996;14:359-68
  • Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio 2014;5:e01074
  • Lam C, Octavia S, Ricafort L, et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates. Australia. Emerging Infect Dis 2014;20:626-33
  • Hegerle N, Guiso N. Bordetella pertussis and pertactin deficient clinical isolates: lessons for pertussis vaccines. Expert Rev Vaccines 2014;13(9):1135-46
  • Bouchez V, Brun D, Dore G, et al. Bordetella parapertussis isolates not expressing pertactin circulating in France. Clin Microbiol Infect 2011;17:675-82
  • Thorstensson R, Trollfors B, Al-Tawil N, et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One 2014;9:e83449
  • Dias WO, van der Ark AAJ, Sakauchi MA, et al. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum Vaccin Immunother 2013;9:339-48
  • Eby JC, Gray MC, Warfel JM, et al. Quantification of the adenylate cyclase toxin of Bordetella pertussis in vitro and during respiratory infection. Infect Immun 2013;81:1390-8
  • Robbins JB, Schneerson R, Kubler-Kielb J, et al. Toward a new vaccine for pertussis. Proc Natl Acad Sci USA 2014;111:3213-16
  • Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014;311:1760-9
  • Health Protection Report. Laboratory confirmed cases of pertussis reported to the enhanced pertussis surveillance programme in England: annual report for 2013. Public Health England; 2014. Available from: www.hpa.org.uk/hpr/archives/2014/hpr1714.pdf [Last accessed 20 May 2014]
  • Amirthalingam G. Effectiveness of maternal pertussis vaccination in England: an observational study. The Lancet 2014. doi:10.1016/S0140-6736(14)60686-3

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.